Navigation Links
Environmental Tectonics Corporation's BioMedical Division Announces New Contract
Date:10/4/2007

SOUTHAMPTON, Pa., Oct. 4 /PRNewswire-FirstCall/ -- Environmental Tectonics Corporation's (Amex: ETC) ("ETC" or the "Company") BioMedical Division announced today a contract award from a medical facility in Louisiana to supply two BARA-MED XD Monoplace Hyperbaric Chambers.

The BARA-MED XD is the industry's most technologically advanced chamber, featuring Windows(R)-based computer control software and automatic record keeping with printout capabilities. The BARA-MED XD also offers the SMOOTH*RIDE(TM) compression/decompression protocol, which is of special importance for patient comfort and safety as well as facility efficiency. ETC's BioMedical Systems Division strives to keep its equipment and customers at the forefront of hyperbaric medicine. In addition to their regular use in clinical treatments at medical facilities around the globe, the BARA-MED XD hyperbaric are routinely involved in the field of research, giving way to possible new HBO frontiers.

Gene Davis, President of ETC's BioMedical Division, commented, " I believe this contract is an affirmation of the company's design and production capability while demonstrating the competitiveness and overall market appeal of the company's BARA-MED XD chambers. ETC plans to continue to supply its customers with both well-designed and technologically advanced products in a competitive market."

ETC designs, develops, installs and maintains aircrew training systems (aeromedical, tactical combat and general), disaster management training systems and services, entertainment products, sterilizers (steam and gas), environmental testing products, hyperbaric chambers and related products for domestic and international customers.

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934. We have based these forward- looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about the Company that may cause our actual results, levels of activity, performance or achievements to be materially different from any other future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements include statements with respect to ETC's vision, mission, strategies, goals, beliefs, plans, objectives, expectations, anticipations, estimates, intentions, financial condition, results of operations, future performance and business of ETC, including but not limited to, (i) projections of revenue, costs of raw materials, income or loss, earnings or loss per share, capital expenditures, growth prospects, dividends, capital structure, other financial items and the effects of currency fluctuations, (ii) statements of plans and objectives of ETC or its management or Board of Directors, including the introduction of new products, or estimates or predictions of actions of customers, suppliers, competitors or regulatory authorities, (iii) statements of future economic performance, (iv) statements of assumptions and other statements about ETC or its business, (v) statements made about the possible outcomes of litigation involving ETC, and (vi) statements preceded by, followed by or that include the words "may", "could", "should", "looking forward", "would", "believe", "expect", "anticipate", "estimate", "intend", "plan", or the negative of such terms or similar expressions. These forward-looking statements involve risks and uncertainties which are subject to change based on various important factors. Some of these risks and uncertainties, in whole or in part, are beyond ETC's control. Factors that might cause or contribute to such a material difference include, but are not limited to, those discussed in our Securities and Exchange Commission filings and other public documents, including, without limitation, our Annual Report on Form 10-K for the fiscal rear ended February 23, 2007. Shareholders are urged to review these risks carefully prior to making an investment in the ETC's common stock.

The Company cautions that the foregoing list of important factors is not exclusive. ETC does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by or on behalf of ETC.

Contact:

Duane D. Deaner, CFO

Environmental Tectonics Corporation

Tel: 215-355-9100 (ext. 1203)

Fax: 215-357-4000

ETC - Internet Home Page: http://www.etcusa.com


'/>"/>
SOURCE Environmental Tectonics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Analysis of Bacterial Assemblage Genetic Diversity in Environmental Samples Using the DCode System
2. Computer recycling: An environmental mandate the private sector can support
3. Environmental group works to run cars on Culvers old frying oil
4. Wisconsins Businesses Can Become Environmental Leaders
5. Corporations and blogging
6. Biomedical engineering conference invites manufacturers
7. Manufacturing partnership will move into biotech and biomedical spaces
8. Biomedical Alliance about more than stem cells
9. Doyle seeks $2.5M for biomedical alliance
10. Students will show off biomedical devices to professors and investors
11. Biomedical alliance marks first full year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... ... , ... A new survey by MedReps ( http://www.medreps.com ), a career site ... medical sales companies to work for in 2020. , The 9th Annual ... the MedReps community to identify which medical sales companies are currently the most sought-after ...
(Date:12/4/2019)... ... December 03, 2019 , ... ... and services, today announced a partnership with the Recombinant Antibody Network (RAN), a ... and UC San Francisco (UCSF) with a common goal to generate recombinant antibodies ...
(Date:12/4/2019)... ... December 03, 2019 , ... Bold Brahim aka Jesse, a Spanish Arabian, was ... After several weeks of medical management, his condition worsened so his owner, Diane, sought ... . Results revealed Jesse had a severe injury to his deep digital flexor tendon ...
(Date:12/4/2019)... , ... December 03, 2019 , ... A new study ... shown can reduce and even reverse fibrosis (scar tissue) buildup – also improves the ... University School of Medicine, was conducted on mice. , The tumor-destroying capabilities of ...
Breaking Biology Technology:
(Date:12/4/2019)... ... December 03, 2019 , ... Genedata, the ... Agenus , a clinical-stage immuno-oncology company developing therapies to fight cancer, has chosen ... Agenus will use the platform to support immunotherapy and vaccine pipeline programs across ...
(Date:12/4/2019)... , ... December 03, 2019 ... ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ... a partnership with Ethicann Pharmaceuticals Inc. (“Ethicann”), a Calgary-based pharmaceutical company using ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... ... that Dr. Marque Todd , a regulatory toxicology expert with more than ... as an Expert Consultant. , Dr. Todd has extensive experience with a ...
Breaking Biology News(10 mins):